Compare IDEXX Laboratories, Inc. (IDXX) vs Indonesia Energy Corporation Limited (INDO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Indonesia Energy Corporation Limited — how do they compare? IDEXX Laboratories, Inc. trades at $516.84 (market cap $40.43B), while Indonesia Energy Corporation Limited trades at $2.77 (market cap $43.24M). The key difference: IDEXX Laboratories, Inc. is far larger — about 935× Indonesia Energy Corporation Limited's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 116,953). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Indonesia Energy Corporation Limited for 24 Days on average.
| IDXX | INDO | |
|---|---|---|
Market Cap | $40.43B | $43.24M |
Volume | 692,164 | 116,953 |
Sector | Health | Energy |
52-Week High | $766.68 | $6.74 |
52-Week Low | $504.70 | $2.49 |
Typical Hold Time | 46 Days | 24 Days |
Enterprise Value | $41.32B | $38.18M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Indonesia Energy Corporation (INDO) trades at $2.79, up 0.72% with bearish technical signals despite 100% analyst buy ratings. The oil and gas explorer shows severe financial distress with negative margins (-152.72% net income) and cash burn, though recent K-29 well discoveries offer operational catalysts. Revenue remains minimal at $2.01M while losses persist, creating high-risk speculation around drilling success.
Outlook hinges on production scaling from new wells, but current fundamentals don't support valuation. High execution risk and cash flow concerns warrant caution despite optimistic analyst coverage. The stock represents a binary bet on operational turnaround versus ongoing financial deterioration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →
